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Abstract 
Introduction: The next-in-class drugs are the original drugs that by chemical structure and 
mode of action similar to their predecessors of the same pharmacological group. The 
clinical development of the next-in-class drugs usually follows the same path as for 
innovative drugs including all phases. Since the effects of the next-in-class drugs can be 
predicted with certain accuracy, there is a potential for optimizing their clinical program in 
terms of duration and costs. Adaptive design represents the innovative approach that allows 
for efficiency and acceleration of drug development. 
Objectives: The study objective was to assess the perspectives of the adaptive design 
methods in clinical development of the next-in-class drugs of different pharmacological 
groups including hypoglycemic agents, anticoagulants and anti-HIV drugs. 
Methods: The adaptive designs were developed and implemented in phase II-III studies of 
three next-in-class drugs. The seamless two-stage design was used for sequential 
assessment of two dosing schemes of gosogliptin (DPP-4 inhibitor), as well as for the dose 
selection and its further efficacy and safety assessment in phase II/III studies of tearxaban 
(factor Xa inhibitor) and elsulfavirine (NNRTI). The measures necessary to control a type 
I error and avoid biases were assumed at all stages. 
Results and discussion: In three conducted trials the non-inferiority of the next-in-class 
drugs to the standards of care was demonstrated as well as comparative or improved safety 
profiles. The adaptive designs allowed for combining two trials/phases in one study 
providing efficient use of resources and expedited market access. 
Conclusion: The adaptive design can be successfully implemented in clinical programs of 
next-in-class drugs. 
Keywords: clinical trials, adaptive design, next-in-class drugs, non-inferiority, type 2 
diabetes mellitus, prevention of venous thromboembolism, HIV, DPP-4 inhibitor, factor 
Xa inhibitor, NNRTI, gosogliptin, tearxaban, elsulfavirine. 
 
Introduction 
The development of similar in 
pharmacotherapeutic effect or improved 
analogues of innovative drugs is one of the main 
focuses for the development of the Russian 
pharmaceutical industry in 2013-2020. The 
mechanisms of the government support of this 
area include the Federal target program 
“Development of the pharmaceutical and medical 
industry of the Russian Federation for the period 
till 2020 and further perspective”, including the 
rules for obtaining the subsidies for the next-in-
class drugs development [1, 2].  
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The next-in-class drugs are original patented 
candidates that affect upon the known biological 
targets and in structure or mode of action similar to 
existing drugs. The development of a next-in-class 
drug can be considered a low-risk R&D strategy due 
to higher predictability of its effects in humans (i.e. 
similar to drugs of the same group), as well as 
possibly better efficacy and safety profiles due to 
“refining” of the original molecule. 
The classic approach to the development of a 
next-in-class drug is the repetition of the clinical 
program of its innovative prototype that imposes 
similar expenses and timelines. Due to high volume 
of investments needed, the scientific and practical 
rationale for such drugs might be of question. Hence 
the pharmaceutical companies require effective 
planning of the clinical trials of the next-in-class 
drugs to ensure their reasonable price and expedited 
market access. 
The adaptive design is one of the innovative 
approaches that allows for conducting clinical 
trials more efficiently (e.g. shorter duration, less 
patients, etc.) or with a higher probability of the 
demonstration of the drug’s effects. The trials that 
use the adaptive design have a predefined 
possibility of modification of some of the design 
or hypothesis aspects based on the results of the 
interim analysis. The data analysis is performed 
according to the predefined plan at preliminary 
specified time points; it may be blinded or 
unblinded, with or without testing of the formal 
statistical hypothesis. 
The first foreign publication describing the 
concept of the adaptive design appeared at the end 
of the 1980s (P. Bauer, K. Köhne, M. Posch, 
J. Wittes, E. Brittain, R.J. Simes) [3, 4, 5, 6, 7]. The 
enthusiasm towards the possibilities of 
implementation of the adaptive design came across 
the critical assessment of the complexity of the 
proposed statistical models. On the other hand, 
during the recent decades the regulatory 
requirements to safety and efficacy assessment have 
been reinforced that made the clinical programs 
more complicated, extended the time for the market 
access, and diminished every possibility for 
optimization of the clinical trial design. 
Nevertheless in the 2000s the regulators of 
different countries indicated the slowdown of the 
innovative sector of the pharmaceutical industry 
that induced some stimulating initiatives such as 
the national US strategy for implementation of the 
innovative approaches to drug development, 
assessment and manufacturing (FDA, 2004). The 
adaptive design was suggested among other 
methods for optimization and acceleration of drug 
development [8, 9]. 
Despite the obvious advantages of the 
adaptive design, this approach might increase the 
risk of biases and misinterpretation of the clinical 
trial results. The choice of statistical methods to 
ensure integrity and validity of study data poses a 
certain difficulty. These aspects are described in 
the EU and US guidelines for the adaptive design 
in clinical trials (EMEA, 2007; FDA, 2010) [10, 
11, 12, 13]. 
In our country the use of the adaptive design 
is limited to the two-stage approach in 
bioequivalence studies, as well as few phase II-III 
trials that altogether are less than 1% of all clinical 
trials in Russia [14, 15, 16]. 
Thus the feasibility assessment of 
implementation of the adaptive design in clinical 
trials of the next-in-class drugs is important for 
the pharmaceutical science and industry. 
Objectives 
The objective of this study was to assess the 
perspectives of the adaptive design methods in 
clinical development of the next-in-class drugs of 
different pharmacological groups including 
hypoglycemic agents, anticoagulants and anti-
HIV drugs. 
Three clinical trial designs were developed in 
order to meet the objective: a phase III clinical 
trial of dipeptidyl peptidase-4 (DPP-4) inhibitor 
gosogliptin in patients with diabetes mellitus 
(DM) type 2, a phase II clinical trial of factor Xa 
inhibitor tearxaban in patients undergoing knee 
replacement surgery, and a phase II-III clinical 
trial of non-nucleoside reverse transcriptase 
inhibitor (NNRTI) elsulfavirine in patients with 
HIV-infection. Upon the trials completion, a 
comparative analysis and economic efficiency 
assessment of the adaptive designs was 
performed. 
Methods 
The clinical trials were conducted in 2012-
2016 in the framework of the technologies 
transfer program financed by the Ministry of 
Industry and Trade of Russia. The study 
documents were reviewed and approved by the 
Ministry of Health of Russia: approval #136 of 
gosogliptin clinical trial dated March 01, 2013 (27 
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sites), approval #485 of tearxaban clinical trial 
dated August 01, 2013 (7 sites), and approval 
#219 of elsulfavirine clinical trial dated April 21, 
2014 (12 sites). 
The studies were conducted in compliance 
with the Guideline for Good Clinical Practice 
(International Conference for Harmonization, 
1996), ethical principles outlined in the 
Declaration of Helsinki (World Medical 
Association, 2013), Russian legislation and 
applicable regulatory requirements (Federal law 
#61, 2010; National industry standard P 52379-
2005) [17, 18, 19]. 
Study designs. The clinical trials were 
prospective multicenter randomized studies with 
active control and two-stage data analysis (the 
adaptive seamless design). In the gosogliptin 
study, the two-stage analysis was used to assess 
the efficacy and safety of the monotherapy at 
Period 1 and then the combination therapy with 
metformin at Period 2 in the same patients’ 
population. In the tearxaban and elsulfavirine 
studies, the interim analysis was used to choose 
the optimal dose of the investigational product 
(Stage 1); then additional patients were enrolled 
in the study in order to assess the efficacy and 
safety of the selected dose (Stage 2) [20].  
Original marketed drugs listed in the national 
standards of care and the Register of vital and 
pivotal drugs of Russia were used as comparators: 
DPP-4 inhibitor vildagliptin (Galvus®, Novartis 
Pharma Stein AG, Switzerland) was used in the 
gosogliptin study; low molecule weight heparin 
enoxaparin (Clexane®, Sanofi-Winthrop Industry, 
France) was used in the tearxaban study; NNRTI 
efavirenz (Stocrin®, Merck Sharp & Dohme B.V., 
the Netherlands) was used in the elsulfavirine 
study. 
The primary efficacy endpoint (PE) in the 
gosogliptin study was the mean change of HbA1c 
at Week 12 (period of monotherapy) and at Week 
36 (period of combination therapy); in the 
tearxaban study it was the composite of all venous 
thromboembolism (VTE) within 6 weeks of the 
knee replacement surgery; in the elsulfavirine 
study it was the rate of achievement of the viral 
load < 400 copies/mL at Week 12 (the surrogate 
endpoint for the interim analysis) and the 
undetectable HIV RNA level at Week 24 (the 
final analysis). 
In the gosogliptin trial, the study treatment 
was not blinded (open study); in the tearxaban and 
elsulfavirine studies the doses of the 
investigational products were blinded at the first 
stage of the studies (partially-blinded study). The 
credibility of the PE assessment was ensured by 
its analysis in the central laboratory or by the 
independent central reviewer; the dose selection 
based on the interim data analysis in the tearxaban 
and elsulfavirine studies was performed based on 
the decision of the Data Monitoring Committee 
(DMC). 
Patients’ population and study procedures. 
Treatment naïve patients with DM type 2 aged 18 
to 78 with body mass index (BMI) of 22 to 40 
kg/m2, HbA1c from 7.5 to 11.0%, fasting plasma 
glucose (FPG) < 15 mmol/L, glomerular filtration 
rate (GFR) ≥ 60 mL/min/1.73m2, with no severe 
acute of chronic complications of DM, significant 
and/or poorly controlled diseases, were enrolled 
in the gosogliptin study. A total of 299 patients 
were randomized to one of two treatment groups: 
gosogliptin or vildagliptin (at 1:1 ratio). The 
duration of the patients’ participation in the study 
was about 42 weeks, including screening  
(1 week), diabetes education and run-in (1 week), 
randomization and the monotherapy period 
 (12 weeks), the combination therapy period  
(24 weeks), and follow-up (4 weeks). The 
following parameters were controlled during the 
study: the state of systems and organs based on 
the physical examination, electrocardiography 
(ECG), and ultrasound; body weight, BMI, blood 
pressure (BP), heart rate (HR), respiratory rate 
(RR), and body temperature; HbA1c, FPG and 
safety laboratory parameters based on 
hematology, biochemistry and urinalysis in the 
central laboratory; pregnancy based on the urine 
pregnancy test; glycemia and hypoglycemic 
episodes based on glucometer and patients’ diary 
data; adverse events (AE). 
Patients aged 18 and older scheduled for the 
planned primary total knee replacement (TKR) 
surgery, with normal coagulation parameters, no 
history of thrombosis or coagulopathy, with no 
active bleeding, significant and/or poorly 
controlled diseases were enrolled in the tearxaban 
study. A total of 200 patients were randomized in 
one of four treatment groups: tearxaban 50 mg, 
100 mg, 150 mg or enoxaparin (at 1:1:1:1 ratio at 
Stage 1 and at 1:1 ratio at Stage 2 after the dose 
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selection). The duration of the patients’ 
participation in the study was about 8 weeks, 
including screening (2 weeks), randomization, 
surgery and study treatment  
(2 weeks: 12 ± 2 days) and follow-up (4 weeks). 
The following parameters were controlled during 
the study: the state of systems and organs based 
on the physical examination and ECG; wound 
assessment, VTE and bleeding symptoms; duplex 
ultrasound scanning, multislice computed 
tomography (MSCT); body weight, BP, HR, RR, 
and body temperature; safety laboratory 
parameters based on hematology, biochemistry, 
coagulation, and urinalysis in the central 
laboratory; pregnancy based on the urine 
pregnancy test; AE. 
Patients aged 18 and older with serologically 
confirmed stable HIV-1 infection (Stage 1-2), 
HIV-1 RNA in plasma ≥ 5 000 copies/mL and 
CD4+ T-lymphocytes count > 200 cells/mm3, 
with no hepatitis B and C, tuberculosis, acute 
infection, significant, and poorly controlled 
diseases, who meet the criteria for starting the 
antiretroviral therapy (ART), were enrolled in the 
elsulfavirine study. A total of 150 patients were 
randomized in one of three treatment groups: 
elsulfavirine 20 mg, 40 mg or efavirenz (at 1:1:1 
ratio at Stage 1 and at 1:1 ratio at Stage 2 after the 
dose selection). The duration of the patients’ 
participation in the study was about 54 weeks, 
including screening (2 weeks), randomization and 
study treatment (48 weeks) and follow-up (4 
weeks). During the study the following 
parameters were controlled: state of systems and 
organs based on the physical examination and 
ECG; body weight, BP, HR, RR, and body 
temperature; HIV-1 RNA load by polymerase 
chain reaction (PCR); CD4+ and CD8+ T-
lymphocytes count, HIV resistance mutations by 
PCR, safety laboratory parameters based on 
hematology, biochemistry, coagulation, and 
urinalysis in the central laboratory; pregnancy 
based on the urine pregnancy test; AE including 
AE of special interest in central nervous system 
(CNS). 
Statistical analysis. The sample size for each 
trial was calculated based on the non-inferiority 
hypothesis to compare two means taking into 
account the standard deviation (the gosogliptin 
study) or to compare proportions taking into 
account the expected results in the study groups 
(the tearxaban and elsulfavirine studies); at the 
significance level of α = 2.5% (one-sided), power 
of 80%, and predefined non-inferiority margin 
[21, 22, 23]. 
The number of patients required for the 
interim analysis was calculated based on the 
Simon’s MiniMax statistical model in the 
tearxaban study and based on the non-inferiority 
hypothesis for the surrogate endpoint in the 
elsulfavirine study. None of the studies assumed 
any repeated testing of the same hypothesis. The 
two-stage statistical analysis didn’t require a type 
I error correction since the null hypothesis should 
have been rejected at both stages of the studies. 
The power of the clinical trials was controlled by 
the algorithm of the patients’ recruitment; the 
power correction was not performed. 
The PE analysis was performed in the full 
analysis set of patients who received at least one 
dose of the study drug and who had at least one 
post-dosing assessment of the PE; in the two-
stage design the patients from both stages were 
included in the analysis. Additional analysis was 
conducted in the per protocol population. The 
safety analysis was conducted in the population of 
patients who received at least one dose of the 
study drug (safety population). 
The statistical analysis was performed in the 
SPSS Statistics and R programs. The 95% 
confidence interval (CI) was calculated for the PE 
and its lower bound was compared to the non-
inferiority margin; based on this comparison it 
was concluded whether the null hypothesis should 
have been confirmed or rejected. The Simon’s 
model was used for the interim analysis in the 
tearxaban study. The differences between the 
means were assessed with the Student’s t-test and 
singe factor ANOVA analysis. The comparison of 
proportions was performed with the Fisher’s 
exact test. The Wilcoxon test was performed for 
non-parametric data. The significance of the 
parameter distribution between the treatment 
groups was assessed with the χ2 criteria. AE were 
coded using the MedDRA dictionary [24, 25]. 
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Results and discussion 
1) Study results of DPP-4 inhibitor 
gosogliptin in patients with DM type 2  
299 patients were randomized in the study 
including 149 patients in gosogliptin group and 
150 patients in vildagliptin group. The treatment 
groups were similar in demographic parameters 
and main baseline characteristics (p > 0.05): sex 
(F 57.7% + M 42.3% vs. F 48.7% + M 51.3%), 
age (55.7 ± 10.0 years vs. 56.7 ± 9.7 years), race 
(Caucasian 98.7%), duration on DM type 2  
(1.7 ± 2.6 years vs. 2.1 ± 3.8 years), baseline 
HbA1c (8.3 ± 1.0% vs. 8.4 ± 1.1%), FPG 
(9.5 ± 2.5 mmol/L vs. 9.5 ± 2.8 mmol/L), body 
weight (90.6 ± 14.8 kg and 91.7 ± 15.6 kg), and 
BMI (32.1 ± 4.3 kg/m2 vs. 31.8 ± 4.3 kg/m2).  
a) Period 1 – Assessment of efficacy and 
safety of monotherapy 
The population for the efficacy assessment 
of the monotherapy consisted of 144 patients on 
gosogliptin and 148 patients on vildagliptin; the 
per protocol population consisted of 134 and 140 
patients; the safety population consisted of 
149 and 150 patients, respectively. 
Upon completion of the monotherapy period, 
the mean change of HbA1c at Week 12 was – 
0.93% in gosogliptin group (decrease from 8.3% 
to 7.4%) and – 1.03% in vildagliptin group 
(decrease from 8.4% to 7.3%); the difference 
between the groups in mean change of HbA1c 
was 0.1% (fig. 1). The null hypothesis that 
gosogliptin was inferior to vildagliptin with 
respect to the PE was rejected and its non-
inferiority was established since the 95% CI upper 
bound of 0.342% was below the non-inferiority 
margin (< 0.4%). The result was confirmed in the 
per protocol population. 
 
 
 
 
a) HbA1c change during 12 weeks of 
monotherapy with DPP-4 inhibitors 
b) Difference between the groups in HbA1c 
change (upper bound of 95% CI < 0.4%) 
Fig. 1. HbA1c change at Week 12 for monotherapy 
 
The analysis of the secondary endpoints after 
12 weeks of monotherapy demonstrated that there 
were no statistically significant differences 
between the groups: 
 the proportion of patients who achieved 
HbA1c ≤ 7.0% was 41.0% on gosogliptin and 
44.5% on vildagliptin (p = 0.52);  
 the FPG decrease was -0.70 mmol/L on 
gosogliptin and -0.89 mmol/L on vildagliptin  
(p = 0.44);  
 the mean change of post-prandial plasma 
glucose was -1.05 mmol/L on gosogliptin and -
1.39 mmol/L on vildagliptin (p = 0.09); 
 the body weight change was -0.54 kg on 
gosogliptin and -0.78 kg on vildagliptin  
(p = 0.44).  
During monotherapy, AE were reported in 37 
(24.8%) patients on gosogliptin and in  
25 (16.7%) patients on vildagliptin. All AE were 
mild or moderate; there were no severe AE. One 
serious adverse event (SAE) not related to the 
study treatment was registered in each group (i.e. 
carcinoma of the pancreas and furuncle, 
respectively). 
AE related to the study treatment were 
reported in 4 (2.7%) patients on gosogliptin (i.e. 
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constipation, allergic dermatitis, increase of 
transaminase levels, asthenia, and dizziness) and 
in 2 (1.3%) patients on vildagliptin (i.e. 
constipation, dizziness, headache).  
During 12 weeks of monotherapy, 
hypoglycemic episodes were registered in 
7 (4.7%) patients on gosogliptin and in 5 (3.3%) 
patients on vildagliptin; those included 
symptomatic episodes in 4 (2.7%) and 2 (1.3%) 
patients, respectively. There were no severe 
hypoglycemic episodes. 
It was concluded that gosogliptin was non-
inferior in efficacy and similar in safety profile to 
vildagliptin while prescribed as monotherapy 
during 12 weeks to patients with DM type 2. The 
patients in both groups who didn’t achieve the target 
glucose parameters by Week 12 rolled-over to the 
combination therapy with metformin and continued 
the treatment for additional 24 weeks. 
b) Period 2 – Assessment of efficacy and 
safety of combination therapy 
The population for the efficacy assessment of 
the combination therapy with metformin 
consisted of 120 patients on gosogliptin and 114 
patients on vildagliptin; the per protocol 
population consisted of 104 and 105 patients; the 
safety population consisted of 122 and 114 
patients, respectively. 
Upon completion of the combination therapy 
with metformin, the mean change of HbA1c at 
Week 36 was -1.29% in gosogliptin group and -
1.35% in vildagliptin group; the difference 
between the groups in mean change of HbA1c 
was 0.06% (fig. 2). The null hypothesis that 
gosogliptin was inferior to vildagliptin with 
respect to the PE was rejected and its non-
inferiority was established since the 95% CI upper 
bound of 0.3% was below the non-inferiority 
margin (< 0.4%). The result was confirmed in the 
per protocol population. 
  
a) HbA1c change during 36 weeks of tretment with 
DPP-4 inhibitors and metformin 
b) Difference between the groups in HbA1c 
change (upper bound of 95% CI < 0.4%) 
Fig. 2. HbA1c change at Week 36 for combination therapy 
 
The analysis of the secondary endpoints at 
Week 36 demonstrated that there were no 
statistically significant differences between the 
groups: 
 the proportion of patients who achieved 
HbA1c ≤ 7.0% was 57.5% on gosogliptin and 
54.4% on vildagliptin (p = 0.74);  
 the FPG decrease was -1.62 mmol/L on 
gosogliptin and -1.64 mmol/L on vildagliptin  
(p = 0.93);  
 the mean change of post-prandial plasma 
glucose was -2.30 mmol/L on gosogliptin and -
2.51 mmol/L on vildagliptin (p = 0.38); 
 the body weight change was -1.02 kg on 
gosogliptin and -1.35 kg on vildagliptin  
(p = 0.48). 
During the combination therapy with 
metformin, AE were reported in 29 (23.8%) 
patients on gosogliptin and in 30 (26.3%) patients 
on vildagliptin. All AE were mild or moderate; 
there were no severe AE. SAE not related to the 
study treatment were registered in 1 (0.8%) 
patient on gosogliptin (i.e. stroke) and in 3 (2.6%) 
patients on vildagliptin (i.e. lumbar 
osteochondrosis, pneumonia, and diabetic 
neuropathy). 
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AE related to the study treatment were 
reported in 4 (3.3%) patients on gosogliptin (i.e. 
dyspepsia, diarrhea, polyposis of gall bladder, 
pancreatitis, cholecystitis, and steatohepatitis 
with increase of total bilirubin and aspartate 
aminotransferase) and in 2 (1.8%) patients on 
vildagliptin (i.e. ventricular extrasystole and 
increase of transaminase). 
Hypoglycemic episodes were registered in 
5 (4.1%) patients on gosogliptin and in 
12 (10.5%) patients on vildagliptin (p = 0.065); 
those included symptomatic episodes in 3 (2.5%) 
and 7 (6.1%) patients, respectively. There were no 
severe hypoglycemic episodes. 
It was concluded that gosogliptin was non-
inferior in efficacy and similar in safety profile to 
vildagliptin while prescribed in combination with 
metformin during 24 weeks to patients with DM 
type 2 [26]. 
2) Study results of factor Xa inhibitor 
tearxaban in orthopedic surgery 
92 patients were enrolled in the study at Stage 
1 including 23 patients in tearxaban 50 mg group, 
22 patients in 100 mg group, 23 patients in 150 
mg group, and 24 patients in enoxaparin group. 
108 patients were additionally enrolled at Stage 2 
including 54 patients in tearxaban 100 mg group 
and 54 patients in enoxaparin group. Thus the 
total number of patients randomized in tearxaban 
100 mg group was 76 and in enoxaparin group 
was 78 (both stages). 
The treatment groups were similar in 
demographic parameters and main baseline 
characteristics (p > 0.05): sex (F 95.2% + M 4.8%, 
F 83.6% + M 16.4%, F 90.0% + M 10.0% vs. 
F 81.6% + M 18.4%), age (67.0 ± 8.2 years, 65.9 ± 
7.4 years, 64.3 ± 7.7 years vs. 63.9 ± 8.3 years), race 
(Caucasian 100.0%), body weight (85.1 ± 13.9 kg, 
86.4 ± 13.7 kg, 87.5 ± 11.3 kg vs. 85.8 ± 13.4 kg) 
and BMI (32.8 ± 5.1 kg/m2, 32.1 ± 4.5 kg/m2, 
32.5 ± 4.8 kg/m2 vs. 31.8 ± 4.1 kg/m2). 
a) Stage 1 – Dose selection 
The population for the efficacy assessment at 
Stage 1 consisted of 21 patients on each tearxaban 
50 mg and 100 mg, 20 patients on tearxaban 150 
mg and 22 patients on enoxaparin; the safety 
population consisted of 21 patients in each group 
of tearxaban and 22 patients on enoxaparin, 
respectively. 
The number of VTE on tearxaban 50 mg 
exceeded the predefined limit (i.e. > 4 VTE in 20 
patients) and was similar to the number of VTE in 
the control group (23.8% and 22.7%, 
respectively). In tearxaban groups of 100 mg and 
150 mg the number of VTE was within the 
predefined limit (14.3% and 5.0%, respectively), 
and the dose of 150 mg showed the best efficacy 
comparing to other doses of tearxaban and 
enoxaparin (fig. 3a).  
Major and clinically relevant non-major 
bleeding within 6 weeks of surgery were reported 
in 2 (9.5%) patients on tearxaban 50 mg, 0 (0.0%) 
patients on tearxaban 100 mg, 1 (4.8%) patient on 
tearxaban 150 mg and in 1 (4.5%) patient on 
enoxaparin (fig. 3b).  
 
a) Total VTE (target rate of VTE ≤ 4 in 
20 patients) 
 
b) Major and clinically relevant non-major 
bleeding rate 
Fig. 3. Risk/benefit analysis for tearxaban dose selection at Stage 1 
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It was concluded that Tearxaban 100 mg had 
the lowest risk of hemorrhage that on top of the 
efficacy results was the reason for choosing this 
dose for further study. 
b) Stage 2 – Assessment of efficacy and 
safety 
The population for the efficacy and safety 
assessment consisted of 73 patients on tearxaban 
100 mg and 76 patients on enoxaparin; the per 
protocol population consisted of 63 and 64 patients, 
correspondingly. 
The absence of VTE was confirmed in 59 (80.8%) 
patients on tearxaban 100 mg and 55 (72.4%) 
patients on enoxaparin; the difference between the 
groups was 8.45% (fig. 4a) The null hypothesis that 
tearxaban 100 mg was inferior to enoxaparin with 
respect to the PE was rejected and its non-inferiority 
was established since the 95% CI lower bound of -
3.01% was above the non-inferiority margin (> -
5%). The result was confirmed in the per protocol 
population. 
There were no fatal events during the study. 
Symptomatic VTE were registered in 2 (2.6%) 
patients on enoxaparin, including 1 (1.3%) case of 
non-fatal pulmonary embolism (PE) that was 
confirmed by MSCT. No symptomatic or 
proximal VTE were registered on tearxaban. 
AE were registered in 21 (28.8%) patients on 
tearxaban 100 mg and 33 (43.4%) patients on 
enoxaparin (p = 0.0629). All AE were mild and 
moderate, not related to the study drug. Cases of 
early discontinuation (ED) of the study treatment 
were related to the surgery complications. SAE 
not related to the study drug were registered in 2 
(2.7%) patients on tearxaban 100 mg and 5 (6.6%) 
patients on enoxaparin.  
Hemorrhage was reported in 1 (1.4%) patient on 
tearxaban 100 mg and 2 (2.6%) patients on 
enoxaparin. Whereas major and clinically relevant 
non-major bleedings were registered in 2 (2.6%) 
patients on enoxaparin and were absent in patients 
on tearxaban 100 mg (fig. 4b). 
 
a) Efficacy – absence of VTE 
(lower bound of 95% CI > -5%) 
 
b) Major and clinically relevant non-major 
bleeding rate 
Fig. 4. Efficacy and safety analysis of tearxaban 100 mg and enoxaparin at Stage 2 
 
It was concluded that tearxaban 100 mg was 
non-inferior in efficacy and had lower risk of 
bleeding than enoxaparin when used for 
prevention of VTE in patients undergoing TKR 
surgery [27]. 
3) Study results of NNRTI elsulfavirine in 
patients with HIV-infection 
90 treatment-naïve patients with HIV-
infection were enrolled in the study at Stage 1 
including 30 patients in each group of 
elsulfavirine 20 mg, 40 mg and efavirenz. 60 
patients were additionally enrolled at Stage 2 
including 30 patients in elsulfavirine 20 mg group 
and 30 patients in efavirenz group. Thus the total 
number of patients randomized in each group of 
elsulfavirine 20 mg and efavirenz was 60 patients 
(both stages). 
The treatment groups were similar in 
demographic parameters and main baseline 
characteristics (p > 0.05): sex 
(F 39.7% + M 60.3%, F 44.8% + M 55.2% vs. 
F 35.1% + M 64.9%), age (35.8 ± 8.7 years,  
35.7 ± 9.7 years vs. 33.4 ± 8.3 years), race 
(Caucasian 98.3-100.0%), as well as duration of  
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HIV-infection from the time the diagnosis was 
established (2.6 ± 2.8 years, 2.4 ± 2.5 years vs. 
2.1 ± 2.6 years), viral load at baseline (4.7 ± 0.6 
log10 copies/mL, 4.9 ± 0.6 log10 copies/mL vs. 
4.8 ± 0.8 log10 copies/mL), body weight (72.1 ± 
15.1 kg, 70.5 ± 14.0 kg vs. 71.2 ± 13.3 kg) and 
BMI (24.3 ± 4.1 kg/m2, 23.7 ± 3.4 kg/m2 vs. 
23.7 ± 2.9 kg/m2). 
a) Stage 1 – Dose selection 
The population for the efficacy assessment at 
Stage 1 consisted of 30 patients in elsulfavirine 20 
mg group, 29 patients in elsulfavirine 40 mg 
group and 27 patients in efavirenz group; the per 
protocol population consisted of 29, 28 and 24 
patients; the safety population consisted of 30, 29 
and 28 patients, respectively. 
The HIV-1 RNA < 400 copies/mL at Week 
12 was achieved by 28 (93.3%) patients on 
elsulfavirine 20 mg, 25 (86.2%) patients on 
elsulfavirine 40 mg and 22 (81.5%) patients on 
efavirenz (fig. 5a). The null hypothesis that 
elsulfavirine 20 mg and 40 mg were inferior to 
efavirenz with respect to the PE was rejected and 
the non-inferiority thereof was established since 
the 95% CI lower bounds of -2.59% and -11.50% 
(respectively) were above the non-inferiority 
margin (> -15%). The result was confirmed in the 
per protocol population. 
AE were reported in 21 (70.0%) patients on 
elsulfavirine 20 mg, 25 (86.2%) patients on 
elsulfavirine 40 mg, and 24 (85.7%) patients on 
efavirenz. AE related to the study treatment were 
reported in 8 (26.6%), 20 (69.0%) and 20 (71.4%) 
patients, respectively. The frequency of adverse 
reactions in patients on elsulfavirine 20 mg was 
2.5 times lower than in patients on elsulfavirine 
40 mg or efavirenz (p < 0.005). AE that caused 
early discontinuation of treatment were registered 
in 1 (3.4%) patient on elsulfavirine 40 mg (rash) 
and in 2 (7.1%) patients on efavirenz (rash and 
allergic reaction). 
AE in CNS were registered in 8 (26.7%) 
patients on elsulfavirine 20 mg, 13 (44.8%) 
patients on elsulfavirine 40 mg and 16 (57.1%) 
patients on efavirenz (fig. 5b).  
 
 
a) Rate of achievement of viral load 
< 400 copies/mL at Week 12  
(lower bound of 95% CI > -15) 
 
b) AE, adverse reactions and AE of special 
interest (CNS) 
Fig. 5. Risk/benefit analysis for elsulfavirine dose selection at Stage 1 
 
It was concluded that elsulfavirine 20 mg had 
the lowest risk of adverse reactions that on top of 
the efficacy results was the reason for choosing 
this dose for further study. 
b) Stage 2 – Assessment of efficacy and safety 
The population for the efficacy assessment of 
the selected dose consisted of 58 patients on 
elsulfavirine 20 mg and 57 patients on efavirenz; 
the per protocol population consisted of 47 and 39 
patients; the safety population consisted of 60 and 
58 patients, respectively. 
The undetectable level of HIV-1 RNA at 
Week 24 was achieved by 49 (84.5%) patients on 
elsulfavirine 20 mg and 38 (66.7%) patients on 
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efavirenz (fig. 6a); the difference between the 
groups was 17.8% (p = 0.031). The null 
hypothesis that elsulfavirine 20 mg was inferior to 
efavirenz with respect to the PE was rejected and 
its non-inferiority was established since the 95% 
CI lower bound of 2.4% was above the non-
inferiority margin (> -15%). The result was 
confirmed in the per protocol population. 
The analysis of the secondary efficacy 
endpoints demonstrated that there were some 
statistically significant differences between the 
groups: 
- the decrease of the viral load (log10 
copies/mL) by Week 12 was -2.8 ± 0.7 on 
elsulfavirine 20 mg and -2.7 ± 1.0 on efavirenz; 
by Week 24 it was -3.3 ± 0.7 and -3.3 ± 0.8; by 
Week 48 it was -3.3 ± 0.7 and -3.4 ± 0.7, 
respectively; 
- the 10-fold decrease of the viral load by 
Week 4 was achieved by 56 (96.6%) patients on 
elsulfavirine 20 mg and 49 (86.0%) patients on 
efavirenz (p = 0.053); 
- 48 weeks of the study treatment were 
successfully completed by 55 (91.7%) patients on 
elsulfavirine 20 mg and 47 (78.3%) patients on 
efavirenz (p = 0.041); 
- the increase of CD4+ T-lymphocytes by 
Week 12 was 112.9 ± 127.6 on elsulfavirine 
20 mg and 78.0 ± 135.8 on efavirenz; by Week 24 
it was 145.0 ± 159.5 and 115.6 ± 168.0; by Week 
48 it was 179.3 ± 156.3 and 182.6 ± 149.1, 
respectively;  
- the decrease of CD8+ T-lymphocytes by 
Week 12 was -60.5 ± 348.2 on elsulfavirine 20 
mg and -143.5 ± 372.9 on efavirenz; by Week 24 
it was -166.9 ± 346.3 and -175.3 ± 402.6; by 
Week 48 it was -214.2 ± 330.1 and -
267.5 ± 401.4, respectively; 
- the HIV-1 drug resistance was not 
established during the trial. 
AE were reported in 46 (76.7%) patients on 
elsulfavirine 20 mg and 50 (86.2%) patients on 
efavirenz. AE related to the study treatment were 
reported in 22 (36.7%) patients on elsulfavirine 20 
mg and 45 (77.6%) patients on efavirenz (fig. 6b). 
The frequency of adverse reactions on 
elsulfavirine 20 mg was twice lower than on 
efavirenz (p < 0.0001). In elsulfavirine 20 mg 
group the following adverse reactions were 
reported in 5-15% patients: headache, increase of 
gamma-glutamyltransferase, mild proteinuria, 
sleep disorder, asthenia, dizziness, and nausea. 
AE of grade 3 and 4 (severe and potentially 
life-threatening) were reported in 5 (8.3%) 
patients on elsulfavirine 20 mg and in 9 (15.5%) 
patients on efavirenz. SAE not related to the study 
drug were reported in 5 (8.3%) patients on 
elsulfavirine 20 mg; among patients on efavirenz, 
SAE were reported in 7 (12.1%) patients, 
including severe allergic reactions and cytolysis 
in 4 (6.9%) patients that were related to the study 
drug. 
AE in CNS were reported in 17 (28.3%) 
patients on elsulfavirine 20 mg and in 36 (62.1%) 
patients on efavirenz (p < 0.001).  
 
a) Rate of achievement of undetectable viral load at 
Week 24 (lower bound of 95% CI > -15; p = 0.031) 
 
b) AE, adverse reactions and AE of special 
interest (CNS) 
Fig. 6. Efficacy and safety of elsulfavirine 20 mg and efavirenz at Stage 2 
It was concluded that elsulfavirine 20 mg was 
non-inferior in efficacy and had lower risk of 
adverse reactions and AE in CNS comparing to 
efavirenz in patients with HIV-infection [28]. 
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4) Comparative analysis and economic 
efficiency assessment of the adaptive designs 
The adaptive seamless design was 
implemented in three clinical trials. In the 
gosogliptin study, the adaptive seamless design 
for two treatment regimens allowed assessing the 
efficacy and safety of the monotherapy (Period 1) 
and then the combination therapy with metformin 
(Period 2) in the same patients’ population 
(fig. 7). In a classic clinical trial model, this would 
require two independent studies with recruitment 
of more patients. 
 
 Period 1 (Monotherapy) Period 2 (Combination)  
Investigational product  
 
 
Comparator  
 
 
  
Interim 
analysis 
Final 
analysis 
Fig. 7. Seamless design for two treatment regimens 
 
The adaptive seamless design of phase II/III 
was used in the tearxaban and elsulfavirine 
studies (fig. 8). The optimal dose of the study 
drug was chosen based on the interim analysis 
(Stage 1); then additional patients were enrolled 
in the study to assess the efficacy and safety of the 
selected dose in the overall patients’ population 
(Stage 2). In a classic clinical trial model, this 
would take longer and require recruitment of 
more patients. 
 
 Stage 1 (Phase II) Stage 2 (Phase III)  
Dose 1 
 
  
Dose 2  
 
 
Comparator  
 
 
  
Interim 
analysis 
Final 
analysis 
 
Fig. 8. Seamless phase II/III design 
 
The comparative analysis of the clinical 
trial designs is presented in Table 1 [29]. 
The implementation of the adaptive design 
methods in the clinical trials of gosogliptin, 
tearxaban, and elsulfavirine provided the average 
decrease of the study budgets by 36% and the 
study duration by 27% 
(i.e. 9 months) as opposed to the classic late-stage 
clinical development program. 
As a result, gosogliptin and elsulfavirine 
have been registered in Russia: Saterex 
(registration certificate No. LP-003598 dated 
May 04, 2016) and Elpida® (registration 
certificate No. LP-004360 dated June 30, 2017). 
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Table 1  
Comparative analysis of clinical trial designs 
 Gosogliptin, DPP-inhibitor Tearxaban, factor Xa inhibitor Elsulfavirine, NNRTI 
Design Multicenter open randomized, Phase III Multicenter partially blinded randomized, 
Phase II 
Multicenter partially blinded randomized, 
Phase II-III 
Adaptation type Seamless design for 2 treatment regimens Seamless phase II/III design Seamless phase II/III design 
Period 1/ Stage 1  Efficacy and safety of monotherapy 
 Gosogliptin / Vildagliptin 
 PE ∆HbA1c (W12-W0) 
 α = 2.5% (1-sided), power 80% 
 non-inferiority, SD = 1.1, δ = 0.4% (95% 
CI), n = 238 (1:1) 
 Dose selection 
 Tearxaban 50 mg, 100 mg, and 150 mg / 
Enoxaparin 40 mg 
 PE % of VTE (W6) 
 α = 5% (2-sided), power 80% 
 Simon’s MiniMax, p0 = 60%, p1 = 85%, r 
≤ 4/20, n = 80 (1:1:1:1) 
 Dose selection 
 Elsulfavirine 20 mg, and 40 mg / 
Efavirenz 600 mg 
 PE % of < 400 copies/mL (W12) 
 α = 5% (1-sided), power 80% 
 non-inferiority, p0 = 80%, p1 = 90%, δ = 
15% (95% CI), n = 75 (1:1:1) 
Interim analysis 
and adaptation 
 Open 
 Central laboratory 
 Increased ED rate to control power 
 No change of design or statistical 
assumptions 
 Unblinded 
 Central reviewer 
 Simon’s model analysis 
 Dose selection based on DMC decision 
 No change of design or statistical 
assumptions 
 Unblinded 
 Central laboratory 
 Analysis of the surrogate endpoint 
 Dose selection based on DMC decision 
 No change of design or statistical 
assumptions 
Period 2/ Stage 2  Efficacy and safety of combination 
therapy  
 Gosogliptin / Vildagliptin  
 PE ∆HbA1c (W36-W0) 
 α = 2.5% (1-sided), power 80% 
 non-inferiority, SD = 1.1, δ = 0.4% (95% 
CI), n = 238 (1:1) 
 Efficacy and safety  
 Tearxaban (selected dose) / Enoxaparin 
 PE % of VTE (W6) 
 α = 2.5% (1-sided), power 80% 
 non-inferiority, p0 = 60%, p1 = 85%, δ = 
5% (95% CI), n = 132 (1:1) 
 Efficacy and safety  
 Elsulfavirine (selected dose) / Efavirenz 
 PE % < 50 copies/mL (W24) 
 α = 2.5% (1-sided), power 80% 
 non-inferiority, p0 = 67%, p1 = 77%, δ = 
15% (95% CI), n = 102 (1:1) 
Estimated number 
of patients per trial 
ED 20% (considering 2 periods) 
Period 1: 300 (150+150), out of which 
Period 2: ~264 (132+132) 
Total: 300 (150+150)  -46.4% 
ED 15% (at each stage) 
Stage 1: 92 (23+23+23+23)  
Stage 2: 108 (54+54) 
Total: 200 (23+77+23+77) -20.0% 
ED 15% (at each stage) 
Stage 1: 90 (30+30+30) 
Stage 2: 60 (30+30) 
Total: 150 (60+30+60)  -27.9% 
Study duration Approval: 01.03.2013 
Report Period 1: 02.07.2014 
Report Period 2: 27.11.2014 
1.7 years (21 months)  -0 months 
Approval: 01.08.2013 
Report Stage 1: 02.10.2014 
Report Stage 2: 26.10.2015 
2.2 years (27 months)  -14 months 
Approval: 21.04.2014 
Report Stage 1: 29.05.2015 
Report Stage 2: 31.05.2016 
2.1 years (25 months)  -13 months 
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Conclusion 
The work demonstrated that the effects of the 
next-in-class drugs in development can be 
predicted with high accuracy due to known 
characteristics of the efficacy and safety of the 
drugs of the same pharmacological group. This 
allows minimizing the risks of using the adaptive 
design methods in clinical programs of the next-
in-class drugs. 
The adaptive design method for two 
treatment schemes can be used in assessment of 
the efficacy and safety of drugs that require dose 
titration and/or stepwise adding of other 
components of the combination therapy.  
The preliminary assessment of efficacy using 
Simon’s statistical model or surrogate endpoint 
prevents from testing the primary hypothesis 
during the interim analysis (for dose selection) 
and provides additional control of the type I error 
in clinical trials with the adaptive seamless phase 
II/III design. 
The results of the study open a new 
perspective for further implementation of the 
adaptive design methods in clinical trials of next-
in-class drugs that will allow for the optimization 
of the development programs and the accelerated 
market access for new drugs.  
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